ID   5NTD_HUMAN              Reviewed;         574 AA.
AC   P21589; B3KQI8; O75520; Q5W116;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   22-JUL-2015, entry version 167.
DE   RecName: Full=5'-nucleotidase;
DE            Short=5'-NT;
DE            EC=3.1.3.5;
DE   AltName: Full=Ecto-5'-nucleotidase;
DE   AltName: CD_antigen=CD73;
DE   Flags: Precursor;
GN   Name=NT5E; Synonyms=NT5, NTE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   GPI-ANCHOR AT SER-549.
RC   TISSUE=Placenta;
RX   PubMed=2129526; DOI=10.1111/j.1432-1033.1990.tb19158.x;
RA   Misumi Y., Ogata S., Ohkubo K., Hirose S., Ikehara Y.;
RT   "Primary structure of human placental 5'-nucleotidase and
RT   identification of the glycolipid anchor in the mature form.";
RL   Eur. J. Biochem. 191:563-569(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=16303743; DOI=10.1093/dnares/12.2.117;
RA   Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J.,
RA   Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S.,
RA   Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y.,
RA   Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S.,
RA   Isogai T.;
RT   "Signal sequence and keyword trap in silico for selection of full-
RT   length human cDNAs encoding secretion or membrane proteins from oligo-
RT   capped cDNA libraries.";
RL   DNA Res. 12:117-126(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-113.
RC   TISSUE=Placenta;
RX   PubMed=8566797; DOI=10.1016/0378-1119(95)00574-9;
RA   Hansen K.R., Resta R., Webb C.F., Thompson L.F.;
RT   "Isolation and characterization of the promoter of the human 5'-
RT   nucleotidase (CD73)-encoding gene.";
RL   Gene 167:307-312(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 359-489, AND VARIANT ALA-376.
RC   TISSUE=Leukocyte;
RA   Zanoni L., Rosi F., Pagani R., Marinello E.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PROTEIN SEQUENCE OF 27-40.
RC   TISSUE=Placenta;
RX   PubMed=2173922; DOI=10.1016/0006-291X(90)91601-N;
RA   Klemens M.R., Sherman W.R., Holmberg N.J., Ruedi J.M., Low M.G.,
RA   Thompson L.F.;
RT   "Characterization of soluble vs membrane-bound human placental 5'-
RT   nucleotidase.";
RL   Biochem. Biophys. Res. Commun. 172:1371-1377(1990).
RN   [7]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-311; ASN-333 AND ASN-403.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-333.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [9]
RP   FUNCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=21933152; DOI=10.1042/BJ20111263;
RA   Garavaglia S., Bruzzone S., Cassani C., Canella L., Allegrone G.,
RA   Sturla L., Mannino E., Millo E., De Flora A., Rizzi M.;
RT   "The high-resolution crystal structure of periplasmic Haemophilus
RT   influenzae NAD nucleotidase reveals a novel enzymatic function of
RT   human CD73 related to NAD metabolism.";
RL   Biochem. J. 441:131-141(2012).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 27-549 IN COMPLEXES WITH ATP
RP   ANALOG AND ZINC IONS, SUBUNIT, GLYCOSYLATION AT ASN-311, AND DISULFIDE
RP   BONDS.
RX   PubMed=23142347; DOI=10.1016/j.str.2012.10.001;
RA   Knapp K., Zebisch M., Pippel J., El-Tayeb A., Muller C.E., Strater N.;
RT   "Crystal structure of the human ecto-5'-nucleotidase (CD73): insights
RT   into the regulation of purinergic signaling.";
RL   Structure 20:2161-2173(2012).
RN   [12]
RP   VARIANT CALJA TYR-358.
RX   PubMed=21288095; DOI=10.1056/NEJMoa0912923;
RA   St Hilaire C., Ziegler S.G., Markello T.C., Brusco A., Groden C.,
RA   Gill F., Carlson-Donohoe H., Lederman R.J., Chen M.Y., Yang D.,
RA   Siegenthaler M.P., Arduino C., Mancini C., Freudenthal B.,
RA   Stanescu H.C., Zdebik A.A., Chaganti R.K., Nussbaum R.L., Kleta R.,
RA   Gahl W.A., Boehm M.;
RT   "NT5E mutations and arterial calcifications.";
RL   N. Engl. J. Med. 364:432-442(2011).
RN   [13]
RP   CHARACTERIZATION OF VARIANT CALJA TYR-358.
RX   PubMed=24887587; DOI=10.1371/journal.pone.0098568;
RA   Fausther M., Lavoie E.G., Goree J.R., Baldini G., Dranoff J.A.;
RT   "NT5E mutations that cause human disease are associated with
RT   intracellular mistrafficking of NT5E protein.";
RL   PLoS ONE 9:E98568-E98568(2014).
CC   -!- FUNCTION: Hydrolyzes extracellular nucleotides into membrane
CC       permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase
CC       activities. {ECO:0000269|PubMed:21933152}.
CC   -!- CATALYTIC ACTIVITY: A 5'-ribonucleotide + H(2)O = a ribonucleoside
CC       + phosphate.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:23142347}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P21589-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21589-2; Sequence=VSP_043076;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Calcification of joints and arteries (CALJA)
CC       [MIM:211800]: A condition characterized by adult-onset
CC       calcification of the lower extremity arteries, including the
CC       iliac, femoral and tibial arteries, and hand and foot capsule
CC       joints. Age of onset has been reported as early as the second
CC       decade of life, usually involving intense joint pain or
CC       calcification in the hands. {ECO:0000269|PubMed:21288095}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the 5'-nucleotidase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NT5EID44492ch6q14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X55740; CAA39271.1; -; mRNA.
DR   EMBL; AK075008; BAG52050.1; -; mRNA.
DR   EMBL; AL135903; CAH72337.1; -; Genomic_DNA.
DR   EMBL; AL589666; CAH72337.1; JOINED; Genomic_DNA.
DR   EMBL; AL589666; CAI40168.1; -; Genomic_DNA.
DR   EMBL; AL135903; CAI40168.1; JOINED; Genomic_DNA.
DR   EMBL; U21730; AAA96950.1; -; Genomic_DNA.
DR   EMBL; AF069067; AAC98672.1; -; Genomic_DNA.
DR   CCDS; CCDS5002.1; -. [P21589-1]
DR   CCDS; CCDS56439.1; -. [P21589-2]
DR   PIR; S11032; S11032.
DR   RefSeq; NP_001191742.1; NM_001204813.1. [P21589-2]
DR   RefSeq; NP_002517.1; NM_002526.3. [P21589-1]
DR   UniGene; Hs.153952; -.
DR   PDB; 4H1S; X-ray; 2.20 A; A/B=27-549.
DR   PDB; 4H1Y; X-ray; 1.58 A; P=27-549.
DR   PDB; 4H2B; X-ray; 1.70 A; A=27-549.
DR   PDB; 4H2F; X-ray; 1.85 A; A=27-549.
DR   PDB; 4H2G; X-ray; 1.55 A; A=27-549.
DR   PDB; 4H2I; X-ray; 2.00 A; A=27-549.
DR   PDBsum; 4H1S; -.
DR   PDBsum; 4H1Y; -.
DR   PDBsum; 4H2B; -.
DR   PDBsum; 4H2F; -.
DR   PDBsum; 4H2G; -.
DR   PDBsum; 4H2I; -.
DR   ProteinModelPortal; P21589; -.
DR   SMR; P21589; 27-549.
DR   BioGrid; 110962; 46.
DR   DIP; DIP-59992N; -.
DR   MINT; MINT-5002487; -.
DR   STRING; 9606.ENSP00000257770; -.
DR   BindingDB; P21589; -.
DR   ChEMBL; CHEMBL5957; -.
DR   DrugBank; DB00987; Cytarabine.
DR   DrugBank; DB00806; Pentoxifylline.
DR   GuidetoPHARMACOLOGY; 1232; -.
DR   DEPOD; P21589; -.
DR   PhosphoSite; P21589; -.
DR   BioMuta; NT5E; -.
DR   DMDM; 112825; -.
DR   MaxQB; P21589; -.
DR   PaxDb; P21589; -.
DR   PRIDE; P21589; -.
DR   DNASU; 4907; -.
DR   Ensembl; ENST00000257770; ENSP00000257770; ENSG00000135318.
DR   Ensembl; ENST00000369651; ENSP00000358665; ENSG00000135318. [P21589-2]
DR   GeneID; 4907; -.
DR   KEGG; hsa:4907; -.
DR   UCSC; uc003pko.4; human. [P21589-1]
DR   UCSC; uc010kbr.3; human. [P21589-2]
DR   CTD; 4907; -.
DR   GeneCards; GC06P086216; -.
DR   HGNC; HGNC:8021; NT5E.
DR   HPA; HPA017357; -.
DR   MIM; 129190; gene.
DR   MIM; 211800; phenotype.
DR   neXtProt; NX_P21589; -.
DR   Orphanet; 289601; Hereditary arterial and articular multiple calcification syndrome.
DR   PharmGKB; PA31804; -.
DR   eggNOG; COG0737; -.
DR   GeneTree; ENSGT00530000063775; -.
DR   HOGENOM; HOG000247215; -.
DR   HOVERGEN; HBG000026; -.
DR   KO; K01081; -.
DR   OMA; WAVIFVL; -.
DR   OrthoDB; EOG7TF78T; -.
DR   PhylomeDB; P21589; -.
DR   TreeFam; TF323589; -.
DR   BioCyc; MetaCyc:HS05981-MONOMER; -.
DR   BioCyc; RETL1328306-WGS:GSTH-3623-MONOMER; -.
DR   Reactome; REACT_1023; Pyrimidine catabolism.
DR   Reactome; REACT_2086; Purine catabolism.
DR   ChiTaRS; NT5E; human.
DR   GeneWiki; NT5E; -.
DR   GenomeRNAi; 4907; -.
DR   NextBio; 18883; -.
DR   PRO; PR:P21589; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; P21589; -.
DR   CleanEx; HS_NT5E; -.
DR   ExpressionAtlas; P21589; baseline and differential.
DR   Genevisible; P21589; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0097060; C:synaptic membrane; IEA:Ensembl.
DR   GO; GO:0008253; F:5'-nucleotidase activity; IDA:CACAO.
DR   GO; GO:0008198; F:ferrous iron binding; IEA:Ensembl.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0046086; P:adenosine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006196; P:AMP catabolic process; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0006259; P:DNA metabolic process; TAS:ProtInc.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:CACAO.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0055086; P:nucleobase-containing small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006144; P:purine nucleobase metabolic process; TAS:Reactome.
DR   GO; GO:0006164; P:purine nucleotide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006195; P:purine nucleotide catabolic process; TAS:Reactome.
DR   GO; GO:0006206; P:pyrimidine nucleobase metabolic process; TAS:Reactome.
DR   GO; GO:0046135; P:pyrimidine nucleoside catabolic process; TAS:Reactome.
DR   GO; GO:0010044; P:response to aluminum ion; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.60.21.10; -; 1.
DR   Gene3D; 3.90.780.10; -; 1.
DR   InterPro; IPR008334; 5'-Nucleotdase_C.
DR   InterPro; IPR006146; 5'-Nucleotdase_CS.
DR   InterPro; IPR006179; 5_nucleotidase/apyrase.
DR   InterPro; IPR004843; Calcineurin-like_PHP_apaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   PANTHER; PTHR11575; PTHR11575; 1.
DR   Pfam; PF02872; 5_nucleotid_C; 1.
DR   Pfam; PF00149; Metallophos; 1.
DR   PRINTS; PR01607; APYRASEFAMLY.
DR   SUPFAM; SSF55816; SSF55816; 1.
DR   SUPFAM; SSF56300; SSF56300; 1.
DR   PROSITE; PS00785; 5_NUCLEOTIDASE_1; 1.
DR   PROSITE; PS00786; 5_NUCLEOTIDASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; GPI-anchor; Hydrolase; Lipoprotein; Membrane;
KW   Metal-binding; Nucleotide-binding; Polymorphism; Reference proteome;
KW   Signal; Zinc.
FT   SIGNAL        1     26       {ECO:0000269|PubMed:2173922}.
FT   CHAIN        27    549       5'-nucleotidase.
FT                                {ECO:0000269|PubMed:2129526}.
FT                                /FTId=PRO_0000000015.
FT   PROPEP      550    574       Removed in mature form.
FT                                /FTId=PRO_0000000016.
FT   REGION      500    506       Substrate binding.
FT   METAL        36     36       Zinc 1.
FT   METAL        38     38       Zinc 1.
FT   METAL        85     85       Zinc 1.
FT   METAL        85     85       Zinc 2.
FT   METAL       117    117       Zinc 2.
FT   METAL       220    220       Zinc 2.
FT   METAL       243    243       Zinc 2.
FT   BINDING     245    245       Substrate.
FT   BINDING     354    354       Substrate.
FT   BINDING     390    390       Substrate.
FT   BINDING     395    395       Substrate.
FT   BINDING     417    417       Substrate.
FT   SITE        118    118       Transition state stabilizer.
FT   SITE        121    121       Transition state stabilizer.
FT                                {ECO:0000305}.
FT   LIPID       549    549       GPI-anchor amidated serine.
FT                                {ECO:0000269|PubMed:2129526}.
FT   CARBOHYD     53     53       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:23142347}.
FT   CARBOHYD    333    333       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    403    403       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID     51     57       {ECO:0000269|PubMed:23142347}.
FT   DISULFID    353    358       {ECO:0000269|PubMed:23142347}.
FT   DISULFID    365    387       {ECO:0000269|PubMed:23142347}.
FT   DISULFID    476    479       {ECO:0000269|PubMed:23142347}.
FT   VAR_SEQ     404    453       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:16303743}.
FT                                /FTId=VSP_043076.
FT   VARIANT     358    358       C -> Y (in CALJA; absence from the
FT                                plasma-membrane; exhibits no catalytic
FT                                AMPase activity).
FT                                {ECO:0000269|PubMed:21288095,
FT                                ECO:0000269|PubMed:24887587}.
FT                                /FTId=VAR_065185.
FT   VARIANT     376    376       T -> A (in dbSNP:rs2229523).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_022091.
FT   VARIANT     379    379       M -> T (in dbSNP:rs2229524).
FT                                /FTId=VAR_048103.
FT   STRAND       27     34       {ECO:0000244|PDB:4H2G}.
FT   STRAND       48     50       {ECO:0000244|PDB:4H2G}.
FT   HELIX        54     56       {ECO:0000244|PDB:4H2G}.
FT   HELIX        61     74       {ECO:0000244|PDB:4H2G}.
FT   STRAND       76     82       {ECO:0000244|PDB:4H2G}.
FT   STRAND       87     90       {ECO:0000244|PDB:4H2G}.
FT   HELIX        91     96       {ECO:0000244|PDB:4H2G}.
FT   HELIX        99    108       {ECO:0000244|PDB:4H2G}.
FT   STRAND      111    114       {ECO:0000244|PDB:4H2G}.
FT   HELIX       117    120       {ECO:0000244|PDB:4H2G}.
FT   HELIX       123    128       {ECO:0000244|PDB:4H2G}.
FT   TURN        129    134       {ECO:0000244|PDB:4H2G}.
FT   STRAND      142    146       {ECO:0000244|PDB:4H2G}.
FT   HELIX       150    154       {ECO:0000244|PDB:4H2G}.
FT   TURN        155    157       {ECO:0000244|PDB:4H2F}.
FT   STRAND      158    166       {ECO:0000244|PDB:4H2G}.
FT   STRAND      169    177       {ECO:0000244|PDB:4H2G}.
FT   HELIX       181    184       {ECO:0000244|PDB:4H2G}.
FT   STRAND      189    193       {ECO:0000244|PDB:4H2G}.
FT   HELIX       196    209       {ECO:0000244|PDB:4H2G}.
FT   STRAND      215    221       {ECO:0000244|PDB:4H2G}.
FT   HELIX       223    232       {ECO:0000244|PDB:4H2G}.
FT   STRAND      238    240       {ECO:0000244|PDB:4H2G}.
FT   STRAND      250    252       {ECO:0000244|PDB:4H2G}.
FT   STRAND      254    256       {ECO:0000244|PDB:4H2G}.
FT   STRAND      263    268       {ECO:0000244|PDB:4H2G}.
FT   STRAND      274    278       {ECO:0000244|PDB:4H2G}.
FT   STRAND      285    294       {ECO:0000244|PDB:4H2G}.
FT   STRAND      300    305       {ECO:0000244|PDB:4H2G}.
FT   HELIX       318    335       {ECO:0000244|PDB:4H2G}.
FT   STRAND      337    344       {ECO:0000244|PDB:4H2G}.
FT   HELIX       350    353       {ECO:0000244|PDB:4H2G}.
FT   HELIX       359    371       {ECO:0000244|PDB:4H2G}.
FT   HELIX       379    381       {ECO:0000244|PDB:4H2F}.
FT   STRAND      386    390       {ECO:0000244|PDB:4H2G}.
FT   HELIX       391    393       {ECO:0000244|PDB:4H2G}.
FT   TURN        401    404       {ECO:0000244|PDB:4H2G}.
FT   STRAND      405    407       {ECO:0000244|PDB:4H2G}.
FT   HELIX       408    414       {ECO:0000244|PDB:4H2G}.
FT   STRAND      420    427       {ECO:0000244|PDB:4H2G}.
FT   HELIX       428    439       {ECO:0000244|PDB:4H2G}.
FT   TURN        440    443       {ECO:0000244|PDB:4H2G}.
FT   STRAND      450    459       {ECO:0000244|PDB:4H2G}.
FT   STRAND      469    475       {ECO:0000244|PDB:4H2G}.
FT   STRAND      477    481       {ECO:0000244|PDB:4H2G}.
FT   STRAND      484    486       {ECO:0000244|PDB:4H2G}.
FT   STRAND      492    498       {ECO:0000244|PDB:4H2G}.
FT   HELIX       499    502       {ECO:0000244|PDB:4H2G}.
FT   HELIX       505    507       {ECO:0000244|PDB:4H2G}.
FT   HELIX       509    514       {ECO:0000244|PDB:4H2G}.
FT   STRAND      516    523       {ECO:0000244|PDB:4H2G}.
FT   HELIX       524    535       {ECO:0000244|PDB:4H2G}.
FT   STRAND      536    538       {ECO:0000244|PDB:4H2G}.
FT   STRAND      544    548       {ECO:0000244|PDB:4H2G}.
SQ   SEQUENCE   574 AA;  63368 MW;  A99AF170AB7EAECE CRC64;
     MCPRAARAPA TLLLALGAVL WPAAGAWELT ILHTNDVHSR LEQTSEDSSK CVNASRCMGG
     VARLFTKVQQ IRRAEPNVLL LDAGDQYQGT IWFTVYKGAE VAHFMNALRY DAMALGNHEF
     DNGVEGLIEP LLKEAKFPIL SANIKAKGPL ASQISGLYLP YKVLPVGDEV VGIVGYTSKE
     TPFLSNPGTN LVFEDEITAL QPEVDKLKTL NVNKIIALGH SGFEMDKLIA QKVRGVDVVV
     GGHSNTFLYT GNPPSKEVPA GKYPFIVTSD DGRKVPVVQA YAFGKYLGYL KIEFDERGNV
     ISSHGNPILL NSSIPEDPSI KADINKWRIK LDNYSTQELG KTIVYLDGSS QSCRFRECNM
     GNLICDAMIN NNLRHTDEMF WNHVSMCILN GGGIRSPIDE RNNGTITWEN LAAVLPFGGT
     FDLVQLKGST LKKAFEHSVH RYGQSTGEFL QVGGIHVVYD LSRKPGDRVV KLDVLCTKCR
     VPSYDPLKMD EVYKVILPNF LANGGDGFQM IKDELLRHDS GDQDINVVST YISKMKVIYP
     AVEGRIKFST GSHCHGSFSL IFLSLWAVIF VLYQ
//
